Antimicrobial peptides (AMPs) are potential alternatives to conventional antibiotics, as they have a fast mode of action, a low likelihood of resistance development and can act in conjunction with existing drug regimens. We report in this study the effects of batroxicidin (BatxC), a cathelicidin-related AMP from Bothrops atrox venom gland, over Trypanosoma cruzi, a protozoan that causes Chagas' disease. BatxC inhibited all T. cruzi (Y strain: benznidazole-resistant) developmental forms, with selectivity index of 315. Later, separate flow cytometry assays showed T. cruzi cell labeling by 7-aminoactinomycin D, the increase in reactive oxygen species and the loss of mitochondrial membrane potential when the parasite was treated with BatxC, which are indication of necrosis. T. cruzi cell death pathway by a necrotic mechanism was finally confirmed by scanning electron microscopy which observed loss of cell membrane integrity. In conclusion, BatxC was able to inhibit T. cruzi, with high selectivity index, by inducing necrosis.
Chagas' disease also known as American trypanosomiasis is one of the world's 13 neglected diseases. According to the World Health Organization an estimated 10 million people are infected worldwide and more than 28 million are at risk of the disease. The causative agent is the flagellated protozoan Trypanosoma cruzi, which is transmitted by a triatomine insect (Volpato et al., 2015; WHO, 2016) .
The current available drugs to treat Chagas' disease, nifurtimox and benznidazole, are only effective in the acute phase, but fails to eradicate the intracellular form of parasites in chronic phase (Morilla and Romero, 2015) . Futhermore, these medicines causes undesirable adverse effects in up to 40% of patients, which include nausea, vomiting, abdominal pain and several neurological effects (Marin-Neto et al., 2009 ).
The search for new molecules with potential anti-T. cruzi activity has been intensified in the field of natural products, with a special emphasis on selective polypeptides from animal venoms. These venom polypeptides and their fractions have stimulated many studies for drug discovery, with some notable successes (Harvey, 2014) . A specific group of molecules derived from such venoms with potential anti-protozoa activities comprises the socalled antimicrobial peptides (AMPs), which have shown activity not only against T. cruzi but also against African trypanosomes and Leishmania spp. Also named host defense peptides, they are amphipathic molecules mainly composed of positively charged (hydrophilic) and hydrophobic residues, which can interact with and disrupt parasite cell membranes (Mcgwire and Kulkarni, 2010; Teixeira et al., 2012 ). An important class of these AMPs regards to the cathelicidins, which are found as multi-effector molecules of the innate immunity in numerous vertebrate animals. All cathelicidins share in common a conserved N-terminal preproregion composed of the signal peptide and the cathelin, cathepsin L inhibitor, domain and a variable C-terminal region which contains the mature sequence responsible for the antimicrobial activity (Gao et al., 2015) .
Recently, our research groups have found and characterized cathelicidin precursors from the venom gland cDNA libraries of several species of South American pit viper snakes, including Crotalus durissus terrificus, C.d. cascavella, Lachesis muta muta, Bothrops atrox and B. lutzi; the deduced mature sequences of these snake venom cathelicidins were collectively named vipericidins (R adisBaptista, 2015) . Batroxicidin, vipericidin from B. atrox, was obtained and it shows good antibacterial activity, especially against Gram-negative species (Falcão et al., 2014) .
In this study, we have evaluated the anti-parasitic effect of batroxicidin, focusing on its potential activity against T. cruzi. This aim was pursued by verifying the cathelicidin-related peptide trypanocidal activity against all protozoan morphological forms. Additionally, the main mechanism that trigger T. cruzi cell death was also investigated followed of the treatment with batroxicidin.
Materials and methods

Chemicals and cells
Batroxicidin
(BatxC) (KRFKKFFKKLKNSVKKRVKKFFRKPRVIGVTFPF-amide; MW ¼ 4258.63 g/mol) was obtained as described by Falcão et al. (2014) . The peptide stock solutions were prepared at 1000 mM with deionized water as required and kept at 4 C for up to six weeks. Beznidazole (Bz) (C 12 (Rodrigues et al., 2014) . Relative viability was determined with parasites treated with only sterile PBS in medium as negative controls (100% viability) and experiments carried out in triplicate.
Batroxicidin activity assay against T. cruzi trypomastigote forms
The trypomastigote forms of T. cruzi were obtained by infecting of LLCMK2 cells with the protozoa (trypomastigote) in T-25/75 cm 2 flasks at 37 C and 5% CO 2 in DMEM medium (Vitrocell, São Paulo, Brazil) supplemented with 1% antibiotics and 2% FBS for 24 h. After that time trypomastigote forms were seeded in 96 well plates and 2-fold serial dilutions of either BatxC or Bz in DMEM were added at the same final concentrations ranges of BatxC and Bz used against the epimastigote forms. After 24 h incubation at 37 C, parasite growth inhibition was quantified in a Neubauer chamber (Adade et al., 2014) . Relative cell viability was calculated with cells treated with only sterile PBS in medium as negative controls and experiments were carried out in triplicate.
BatxC cytoxicity evaluation toward LLC-MK2 cells
Cell viability was also measured using a standard MTT assay (Vanden Berghe et al., 2013) . LLC-MK2 cells were plated in the DMEM medium, treated with different concentrations of BatxC and incubated at 37 C for 24 h. MTT (Amresco, Ohio, USA; 5 mg/mL) was added and the cells were incubated for 4 h, when 10% Sodium dodecyl sulphate (SDS; Vetec, São Paulo, Brazil) was added to solubilize the formazan product. Cell viability measurements were performed at 570 nm on a microplate reader (Biochrom ® Asys Expert Plus). Relative cell viability was calculated with cells treated with only sterile PBS in medium as negative controls and experiments were carried out in triplicate. The Selectivity index (SI) was calculated by the ratio of cytotoxic/trypanocidal activity (Nwaka and Hudson, 2006).
Batroxicidin activity assay against T. cruzi amastigote forms
LLC-MK2 cells were seeded in 24-well plates (5 Â 10 5 /well) containing at the bottom glass coverslips (13-mm diameter) and cultured in DMEM medium supplemented with 10% FBS and 1% antibiotics, at 37 C, in a 5% CO2 atmosphere, for 24 h. Next, the media was removed from the wells and LLC-MK2 cells were infected with trypomastigote forms (parasite: host cell ratio of 20:1) in DMEM medium containing 2% FBS. After 48 h of incubation, the cells were washed to remove the non-internalized parasites and treated with either BatxC (0.44 or 0.88 mM) or Bz (282 or 564 mM) in DMEM medium with 2% FBS. After incubation for 24 or 48 h at 37 C, the coverslips were collected, washed with PBS, fixed in Bouin's solution and stained with Giemsa (Lima et al., 2016) . Infected LLC-MK2 not treated with either Bz and BatxC peptide cells were used as controls and the number of intracellular amastigotes per 100 cells was counted in triplicates.
T. cruzi epimastigote death pathway assays
Experiments of flow cytometry were performed to investigate and evaluate the pathways by which BaxtC induces T. cruzi death. The epimastigote forms were treated with BatxC at their respective IC 50 and 2x IC 50 concentrations (11.3 and 22.6 mM) in Liver Infusion Tryptose medium. After incubation for 6 and 24 h at 28 C, the parasite cells were washed and stained with FITC-annexin V (Ax) and/or 7-AAD according to the manufacturer's instructions (BD Pharmingen, California, USA) to evaluate cell death by apoptosis or necrosis. In separate experiments, the mitochondrial transmembrane potential, the reactive oxygen species (ROS) and the swelling of reservosomes were also assessed. After treatment of T. cruzi epimastigote forms with BatxC at its IC50 (11.3 mM) for 6 and 24 h at 28 C, the parasites were stained with 10 mg/mL Rhodamine 123 or 20 mMol/L DCFH-DA or 5 mg/mL Acridine Orange (Sigma e Aldrich™, St. Louis, MO), according to the manufacturer's instructions, respectively. Next, these parasite samples were run in a FACSCalibur flow cytometer (Becton-Dickinson, San Jose, CA), in which 10,000 live events were collected and analyzed by means of the Cell Quest software (Becton-Dickinson, San Jose, CA). Epimastigotes without BatxC treatment were used as controls and experiments were carried out in triplicate.
Scanning electron microscopy (SEM)
Epimastigote forms were treated with BatxC peptide at its IC 50 (11.3 mM) concentration in Liver Infusion Tryptose medium. After incubation for 24 h at 28 C, the parasites were washed with PBS and fixed with a 2.5% glutaraldehyde (Electron Microscopy Sciences, Hatfield, Pennsylvania) solution. After fixation for 2 h at Room Temperature, parasites were washed with PBS, and then dehydrated with ethanol. Next, samples were dried with CO 2 , coated with gold and, finally, observed in a FEG Quanta 450 scanning electron microscope (FEI, Oregon, USA). Digital images were acquired with its respective software and stored (Lima et al., 2016) .
Statistical analysis
All tests were performed in triplicate. The statistical analysis was performed using the GraphPad Prism 5 program (GraphPad Software, San Diego, CA, USA). IC50 and LC 50 values were determined by nonlinear regression. Data were analyzed using one-way analysis of variance (ANOVA) followed by Dunnett's post-test. Significance was defined as *p < 0.05.
Results
BatxC peptide was tested against all three morphological forms of T. cruzi to evaluate the antichagasic activity and compare its effect with commercially available drugs, such as Bz. The concentrations of BatxC and Bz to inhibit 50% (IC 50 ) of epimastigotes and trypomastigotes after different time of incubation are presented in Table 1 .
T. cruzi trypomastigote forms were also susceptible to BatxC treatment with an IC 50 as low as 0.44 mM while Bz needed 282 mM to kill 50% of the these parasite life forms after 24 h of incubation. We also tested the peptide cytoxicity with uninfected LLC-MK2 cells to ascertain the BatxC selective activity against the T. cruzi. According to Fig. 1A (IC 50 ) and 22.6 mM (2x IC 50 ) for 6 h resulted in an increase in 7-AAD labeled (upper left quadrant) parasites (17% and 12% respectively) compared to non-treated cells (0.7%). When the parasites were treated for 24 h, the percentage of 7-AAD labeled cells increased for both concentrations (27%), indicating that T. cruzi death occurs predominantment by necrosis. Two additional assays checked the generation of ROS and the disruption of mitochondrial transmembrane potential that corroborates the mechanism of parasite death. Fig. 3A shows that T. cruzi epimastigotes treatment with BatxC at its IC 50 resulted in the generation of ROS, as identified by the increase of DCFH-DA fluorescent signal (shift to the right), especially after 24 h of incubation, compared to the non-treated parasites. Meanwhile, when rhodamine 123 was used, epimastigotes treated with 11.3 mM of the peptide exhibited a gradual decrease (shift to the left) in fluorescence emission, which it is noticed in particular after 24 h of incubation, suggesting alteration of mitochondrial transmembrane potential in BatxC-treated parasites (Fig. 3B) .
Autophagy cell death was also investigated to verify whether there were other pathways of induced death besides necrosis. T. cruzi treated with BatxC (at its IC 50 ) were incubated with acridine orange to detect swelling of the reservosomes that are acidic vesicles. After 6 and 24 h of incubation, however, flow cytometry analysis (Fig. S1 ) did not show any significant fluorescent signal increment compared to non-treated T. cruzi.
Finally, scanning electron microscopy (SEM) images with were expressed between parentheses. IC50 values are expressed in mM. Data are expressed as means ± SEM of 3 independent experiments; nd, Not determined). epimastigotes treated for 24 h with the BatxC peptide (11.3 mM)
were obtained that are displayed in Fig. 4 . Comparison of a nonpeptide-treated epimastigote (Fig. 4A ) and peptide-treated, revealed that the parasite cellular membrane became severely damaged ( Fig. 4BeD) with the presence of pores (Fig. 4C ), when treated with BatxC, which are typical evidences of necrosis and corroborate the biochemical evidences of such mechanism of peptide action, confirming the flow cytometry data.
Discussion
There is a constant and urgent need to discover and develop new drugs for the treatment of neglected tropical diseases. For Chagas' disease, one of these neglected diseases, the only two available drugs are nirfutimox and benzimidazole. They are only effective in the acute phase and cause severe toxic side-effects in adults (Morilla and Romero, 2015) . Furthermore, Bz was developed more than 40 years ago and some benznidazole-resistant strains have already appeared (Rodrigues et al., 2014) . Batroxicidin, cathelicidin-related peptide, exhibited anti-Trypanosoma cruzi activity against all developmental forms of a benznidazole-resistant strain of T. cruzi with necrotic pathway involved in a proliferative form.
T. cruzi can assume three different morphological forms along their life cycle, which depend on the interaction with a host or a reservoir; they are epimastigote (the proliferative insect vectorborne stage), trypomastigote (the infective, non-proliferative form) and amastigote (intracellular proliferative form) (Adade et al., 2013) . The proliferative forms, amastigote and epimastigote, have similar structure of a kinetoplast, a complex structure bearing the mitochondrial genome (De Souza, 2002; Girard et al., 2016) . The similarity of kinetoplast from these two forms and the easily maintenance in cultures became epimastigote forms interesting to study cell death pathway. Trypomastigote and amastigote forms were obtained by infection of mammalian cells LLC-MK2. This renal cell line supports a high percentage of infected cells, high interiorization index (parasites/cell) and high number of trypomastigotes releases (Zingales et al., 1982 (Zingales et al., , 1997 Andrews and Colli, 1982) .
Vipericidins, AMPs cathelicidins from pit viper gland venoms, have shown antimicrobial and anti-cancer activity (Falcão et al., 2014 (Falcão et al., , 2015 Cavalcante et al., 2016) . In this study, we tested the vipericidin BatxC against Trypanosoma cruzi and mammalian cells.
Facing the challenge of developing new drugs, the safety superior to Bz is mandatory (Morilla and Romero, 2015) . Importantly, BatxC displayed a low toxicity toward LLC-MK2 host cells. Considering the LC50 concentrations against the trypomastigotes, BatxC SI was 315, while Bz SI was only 2.18, which shows that BatxC peptide possesses a greater selectivity than Bz against the T. cruzi Y strain. Moreover, BatxC SI was well above the minimum required (SI ! 50) by the WHO/TDR guidelines for a potential drug candidate against T. cruzi to be considered as a hit (Nwaka and Hudson, 2006) . BatxC also was able to reduce the number of amastigote forms at concentrations of 0.44 and 0.88 mM, while Bz showed effect in concentrations of 280 and 560 mM. These concentrations were chosen based on their LC50 of trypomastigotes, the blood circulating form.
Other cathelicidins have also shown anti-protozoan activity by killing both insect and bloodstream forms of the parasite Trypanosoma brucei through disruption of cell membrane integrity, which decreased parasitemia and prolonged mice survival with late-stage T. brucei infection (McGwire et al., 2003) . In addition, eCATH1 (equine cathelicidin) was able to kill Trypanosoma brucei brucei, Trypanosoma evansi and Trypanosoma equiperdum causing plasma membrane permeabilization and disruption of mitochondrial membrane potential (Cauchard et al., 2016) .
BatxC also was able to decrease transmembrane potential of mitochondria of a proliferative form, showing promising trypanocidal activity. Generation of ROS has been observed in parasites treated with BatxC, as well treated with Bz (Rigalli et al., 2016) , but BatxC have showed more safety in this work.
In this study, BatxC was able to kill the etiologic agent of Chagas' disease, T. cruzi. The labelling with 7AAD and 7AAD/AX in BatxCtreated parasites at two periods indicates lysis of the cell membrane a short and long time, confirmed by MEV, which showed degradation of cellular membrane with pores. All of the observed morphological changes in addition to the flow cytometry data suggest that BatxC causes necrotic cell death in T. cruzi. The hallmarks of this type of death involve alterations in mitochondria, including mitochondrial depolarization, ATP depletion, generation of ROS, loss of calcium homeostasis, cytoplasmic vacuolization and, ultimately, breakdown of the plasma membrane (Menna-Barreto et al., 2009) .
Recently, it demonstrated that AMPs possess membrane lytic activities that are naturally designed to target the cellular membrane of pathogens (Sani and Separovic, 2016) , but it could be related to hemolytic effect. BatxC has low hemolytic effect, reaching 10% hemolysis at 12.5 mM (Falcão et al., 2014) . Different cell death pathways were found in some AMPs from animal venom tested against T. cruzi. Melittin caused apoptosis and autophagy in T. cruzi (Adade et al., 2013) . In our work, autophagic cell death by BatxC was also investigated but no evidences were observed with the acridine orange assay.
The most important findings of the present study were the activity of BatxC against the amastigote form and the high selective index. Amastigotes maintain the infections by T. cruzi and BatxC concentrations more than 300 times lower to those required to cause damage to host cells can inhibit amastigote proliferation.
In conclusion, BatxC, a cathelicidin-related peptide from the venom gland of Bothrops atrox, not only has antibacterial properties but also exhibited anti-T. cruzi activity. Moreover, all T. cruzi morphological forms (epimastigotes, trypomastigotes and amastigotes) were susceptible to the BatxC, which can kill the epimastigote parasite form by inducing necrosis. Noteworthy, the peptide greater selectivity for T. cruzi trypomastigote forms than Bz, compared to activity against healthy mammalian cells, make BatxC a promising drug candidate or a lead for the development of new drugs to treat Chagas' disease.
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